Clinical Trial: Percutaneous Transhepatic Cholangiography (PTHC) in Acute Cholecystitis and Clinical Outcomes

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational [Patient Registry]

Official Title: Percutaneous Drainage in a Setting of Acute Cholecystitis Severity Grade III and Correlation With Clinical Outcomes

Brief Summary: In a setting of acute cholecystitis (AC) one of the treatment option is percutaneous transhepatic cholangiography (PTHC) drainage. The goal of current study is to evaluate some radiology aspects and correlate with clinical patient outcomes in patients with acute cholecystitis severity grade III (presented as acute cholecystitis with organ dysfunction).

Detailed Summary:
Sponsor: University of Split, School of Medicine

Current Primary Outcome: C-reactive protein (CRP) [ Time Frame: Up to 8 weeks. ]

C-reactive protein (CRP) is a protein found in blood plasma, whose levels rise in response to inflammation.


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Drainage duration (expressed in days) [ Time Frame: Up to 16 weeks. ]
    The drain which is placed in gallbladder during Percutaneous transhepatic cholangiography (PTHC) remains there until resolving clinical parameters of acute cholecystitis.
  • White blood cells (WBCs) count [ Time Frame: Up to 8 weeks. ]
    White blood cells (WBCs) are the cells of the immune system. During inflammation White blood cell level rise.


Original Secondary Outcome: Same as current

Information By: University of Split, School of Medicine

Dates:
Date Received: March 7, 2017
Date Started: January 1, 2015
Date Completion: June 1, 2019
Last Updated: March 21, 2017
Last Verified: March 2017